FA
XENT

Friess Associates’s Intersect ENT, Inc XENT Stock Holding History

Friess Associates’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-93,587
Closed -$3.5M – 141
2018
Q2 		$3.5M Sell
93,587
-200,013
-68% -$7.85M 0.28% 71
2018
Q1 		$11.5M Buy
+293,600
New +$10.7M 0.94% 52

Other funds holding XENT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Friess Associates's XENT Position: Q3 2018 in Review

Friess Associates sold out of Intersect ENT, Inc (XENT) in Q3 2018, closing a stake of 93,587 shares — an estimated $3.5M sold.

Friess Associates first reported a position in XENT in Q1 2018 and held it in 2 quarters. The position peaked at $11.5M in Q1 2018. 138 funds tracked by Wall St. Rank hold XENT as of Q3 2018.

  • Friess Associates reported no remaining Intersect ENT, Inc position as of Q3 2018 after selling out during the quarter.
  • Friess Associates sold 93,587 Intersect ENT, Inc shares in Q3 2018, an estimated $3.5M.
  • Friess Associates first reported a position in Intersect ENT, Inc in Q1 2018 and held it in 2 quarters.
  • Friess Associates's Intersect ENT, Inc position peaked at $11.5M in Q1 2018.
  • 138 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q3 2018.

Based on Friess Associates's 13F filing for Q3 2018, filed 14 Nov 2018.